Association of IRF5 polymorphisms with susceptibility to hemophagocytic lymphohistiocytosis in children

Journal of Clinical Immunology

Volumn 31, Issue 6, 2011, Pages 946-951

  Yanagimachi, Masakatsu ^a   Goto, Hiroaki ^a   Miyamae, Takako ^a   Kadota, Keisuke ^a   Imagawa, Tomoyuki ^a   Mori, Masaaki ^a   Sato, Hidenori ^b   Yanagisawa, Ryu ^c   Kaneko, Tetsuji ^a   Morita, Satoshi ^a   Ishii, Eiichi ^d,e   Yokota, Shumpei ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DNA CHIP RESEARCH INC   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e HLH Study Committee   (Japan)

Author keywords

Hemophagocytic lymphohistiocytosis; Interferon regulatory factor 5; Polymorphism

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; IMMUNE RESPONSE; INTERFERON REGULATORY FACTOR 5 GENE; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; CYTOKINES; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT; INFLAMMATION MEDIATORS; INTERFERON REGULATORY FACTORS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION; MALE; POLYMORPHISM, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84857050020     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9583-x     Document Type: Article

References (38)

1. Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol. 2010;6(1):137-54.
2. Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21(5):245-53. (Pubitemid 47212601)
3. Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 1991;80(4):428-35.
4. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-31. (Pubitemid 44958267)
5. + T cells and interferon gamma are essential for the disorder. Blood. 2004;104 (3):735-43. (Pubitemid 38970567)
6. Marcenaro S, Gallo F, Martini S, Santoro A, Griffiths GM, Arico M, et al. Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood. 2006;108(7):2316-23. (Pubitemid 44497515)
7. Schneider EM, Lorenz I, Muller-Rosenberger M, Steinbach G, Kron M, Janka-Schaub GE. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood. 2002;100(8):2891-8.
8. Akashi K, Hayashi S, Gondo H, Mizuno S, Harada M, Tamura K, et al. Involvement of interferon-gamma and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br J Haematol. 1994;87(2):243-50.
9. Imashuku S, Hibi S, Sako M, Ishii T, Kohdera U, Kitazawa K, et al. Heterogeneity of immune markers in hemophagocytic lymphohistiocytosis: comparative study of 9 familial and 14 familial inheritance-unproved cases. J Pediatr Hematol Oncol. 1998;20(3):207-14. (Pubitemid 28280896)
10. Ohga S, Matsuzaki A, Nishizaki M, Nagashima T, Kai T, Suda M, et al. Inflammatory cytokines in virus-associated hemophagocytic syndrome. Interferon-gamma as a sensitive indicator of disease activity. Am J Pediatr Hematol Oncol. 1993;15(3):291-8. (Pubitemid 23217955)
11. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2007;166(2):95-109. (Pubitemid 46025500)
12. Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115(4):461-73. (Pubitemid 37456808)
13. Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007;86(1):58-65. (Pubitemid 47204491)
14. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446):1957-9. (Pubitemid 129515904)
15. zur Stadt U, Schmidt S, Kasper B, Beutel K, Diler AS, Henter JI, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005;14(6):827-34. (Pubitemid 40403278)
16. zur Stadt U, Rohr J, Seifert W, Koch F, Grieve S, Pagel J, et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet. 2009;85(4):482-92.
17. Fisman DN. Hemophagocytic syndromes and infection. Emerg Infect Dis. 2000;6(6):601-8. (Pubitemid 32110502)
18. Rouphael NG, Talati NJ, Vaughan C, Cunningham K, Moreira R, Gould C. Infections associated with haemophagocytic syndrome. Lancet Infect Dis. 2007;7(12):814-22. (Pubitemid 350152044)
19. Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol. 2010;22(5):561-6.
20. Kelly A,Ramanan AV. Recognition and management ofmacrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol. 2007;19(5):477-81. (Pubitemid 47344241)
21. Yanagimachi M, Naruto T, Miyamae T, Hara T, Kikuchi M, Hara R, et al. Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis. J Rheumatol. 2011;38:769-74.
22. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature. 2005;434 (7030):243-9. (Pubitemid 40388058)
23. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001;19:623-55. (Pubitemid 32368048)
24. Henter JI, Arico M, Egeler RM, Elinder G, Favara BE, Filipovich AH, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH Study Group of the Histiocyte Society. Med Pediatr Oncol. 1997;28(5):342-7.
25. Arico M, Janka G, Fischer A, Henter JI, Blanche S, Elinder G, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 1996;10(2):197-203. (Pubitemid 26102881)
26. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-2. (Pubitemid 38160763)
27. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146(5):598-604. (Pubitemid 40616243)
28. Matsuda K, Nakazawa Y, Yanagisawa R, Honda T, Ishii E, Koike K. Detection of T-cell receptor gene rearrangement in children with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis using the BIOMED-2 multiplex polymerase chain reaction combined with GeneScan analysis. Clin Chim Acta. 2011;412:1554-8.
29. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics. 2007;23(5):644-5. (Pubitemid 46522604)
30. Lake SL, Lyon H, Tantisira K, Silverman EK, Weiss ST, Laird NM, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered. 2003;55(1):56-65. (Pubitemid 36928747)
31. Shimane K, Kochi Y, Yamada R, Okada Y, Suzuki A, Miyatake A, et al. A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population. Ann Rheum Dis. 2009;68(3):377-83.
32. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet. 2006;38(5):550-5.
33. Henter JI, Ehrnst A, Andersson J, Elinder G. Familial hemophago-cytic lymphohistiocytosis and viral infections. Acta Paediatr. 1993;82 (4):369-72. (Pubitemid 23142852)
34. Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol. 2002;22(16):5721-40. (Pubitemid 34815822)
35. Hao S, Li P, Zhao J, Hu Y, Hou Y. 17beta-estradiol suppresses cytotoxicity and proliferative capacity of murine splenic NK1.1+ cells. Cell Mol Immunol. 2008;5(5):357-64.
36. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. IRF5 promotes inflammatory macrophage polarization and T (H)1-T(H)17 responses. Nat Immunol. 2011;12(3):231-8.
37. Krausgruber T, Saliba D, Ryzhakov G, Lanfrancotti A, Blazek K, Udalova IA. IRF5 is required for late-phase TNF secretion by human dendritic cells. Blood. 2010;115(22):4421-30.
38. Sumazaki R, Kanegane H, Osaki M, Fukushima T, Tsuchida M, Matsukura H, et al. SH2D1A mutations in Japanese males with severe Epstein-Barr virus-associated illnesses. Blood. 2001;98 (4):1268-70.